Can existing heparanase inhibitors selectively target pathological tau without disrupting physiological HSPG functions?

drug-development open
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
—
Novelty
—
Mechanistic
—
Druggability
—
Priority
71%
Importance
—
Tractability
—
Market price
50%

Description

The Domain Expert identified safety concerns about non-selective HSPG effects but the therapeutic window remains unexplored. Determining whether spatial or temporal selectivity is achievable could enable clinical translation of glycocalyx-targeting approaches.

Source: Debate session sess_SDA-2026-04-01-gap-005 (Analysis: SDA-2026-04-01-gap-005)